ASH Q2 2026 Earnings Call Summary

Summary of Ashland's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

Sales: $482 million, up 1% year-over-year.
Adjusted EBITDA: $98 million, down 9% year-over-year; adjusted EBITDA margin at 20%, down 220 basis points.
Adjusted EPS: $0.91, down 8% year-over-year.
Operating Cash Flow: $50 million, significantly up from $9 million in the prior year.
Free Cash Flow: $29 million, driven by working capital improvements.
Net Debt: Just over $1 billion, with a net leverage ratio of approximately 2.7x.
Liquidity: Total available liquidity of approximately $939 million.

2. Strategic Updates and Business Highlights

Life Sciences: Steady performance driven by resilient pharmaceutical demand, particularly in injectables and high-purity excipients.
Personal Care: Broad-based growth with strong volume gains, particularly in biofunctional actives and microbial protection.
Specialty Additives: Mixed market conditions; coatings volumes grew while construction sales declined due to portfolio mix actions.
Intermediates: Operating in a stable but trough level environment, impacted by the Calvert City outage.
Innovation and Globalization: Strong momentum with new product introductions exceeding full-year targets after just two quarters.

3. Forward Guidance and Outlook

Sales Guidance: Updated to $1.835 billion to $1.87 billion for fiscal 2026.
Adjusted EBITDA Guidance: Revised to $385 million to $400 million.
Adjusted EPS Growth: Expected mid-single to high-single-digit growth.
Free Cash Flow Conversion: Anticipated at approximately 50% of adjusted EBITDA.
Market Expectations: Resilient demand in Life Sciences and Personal Care, while Specialty Additives and Intermediates are expected to remain stable at trough levels.

4. Bad News, Challenges, or Points of Concern

Operational Headwinds: Specific issues at the Hopewell plant affected productivity and performance; Calvert City outage also impacted results.
Pricing Pressure: Modest pricing declines year-over-year, primarily due to carryover impacts from prior pricing actions.
Geopolitical Risks: Limited exposure to the Middle East, but ongoing geopolitical tensions could impact demand and pricing dynamics.
Market Uncertainty: Caution regarding demand recovery in North America and Europe, particularly in coatings.

5. Notable Q&A Insights

Pricing Dynamics: Executives emphasized the importance of managing pricing to offset cost increases, with expectations for price increases to flow through in the coming months.
Life Sciences Demand: Confidence in the resilience of pharma demand, with expectations for growth in the second half of the year despite some softness in non-pharma segments.
Specialty Additives Outlook: Expected to see year-over-year declines in operating income due to ongoing operational challenges.
2027 Outlook: While specifics were not provided, management indicated a focus on operational improvements and maintaining competitive cost structures, with expectations for continued growth in Life Sciences and Personal Care.

Overall, Ashland reported a mixed performance in Q2 2026, with resilient demand in key segments but facing operational challenges that impacted financial results. The company remains focused on strategic initiatives to drive innovation and improve execution while navigating a complex market environment.

ASH — Ashland Inc.